The science times publishes article about jaguar health's focus on developing crofelemer for two rare disease indications

Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the eu and middle east/north africa regions, with results expected before the end of 2023 and in 2024 san francisco, ca / accesswire / august 30, 2023 / jaguar health, inc. (nasdaq:jagx), a commercial-stage pharmaceuticals company developing first-in-class plant-based gastrointestinal (gi) prescription medicines, today announced that an article about the company's focus on developing its novel plant-based prescription drug crofelemer for two rare disease indications, short bowel syndrome (sbs) and microvillus inclusion disease (mvid), was published august 23, 2023 in the science times. the article, titled "jaguar health supports investigator initiated trials for crofelemer to treat two rare intestinal diseases," can be viewed by clicking here.
JAGX Ratings Summary
JAGX Quant Ranking